Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Hagerty, Inc.

HGTY
Financials · Insurance - Property & Casualty

Hagerty, Inc. is cheap for a reason. The P/BV sits at the 15th percentile of its own range, and the quarters are still getting worse.

The sharpest disagreement: annual EPS moved +270.0% against a +17.0% price move — the market has not yet caught up with the delivery.

The price is in a confirmed uptrend (1 weeks in) while the P/BV sits at the 15th percentile of its own 5-year range. Underneath, the last four quarters read deteriorating — profit −133.3% year on year, with the the net margin at −3.2%. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
partial read
Price
$11.7
+17.0% 1Y
P/BV
5.4×
15th pctile
of its own 5-year range
Revenue (Mar 26)
$0.3 B
−6.1% YoY
Profit (Mar 26)
$−0.0 B
−133.3% YoY
Net margin
−3.2%
−12.3 pp YoY
ROE
15%
FY25
ROA
5.98%
latest
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Hagerty, Inc. trades at $11.7, in a confirmed uptrend and 1 weeks into that stage. That is +0.7% against its own 200-day average. It sits at 44% of a 52-week range of $10 to $14. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks.

Today the stock is in a confirmed uptrend — week 1 of stage 2. At $11.7 it trades +0.7% versus its 200-day average and sits at 44% of its 52-week range ($10–$14).

Aug 26: $11.7 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+0.7% versus the 200-day line, week 1 of stage 2
Price50-day avg200-day avg
S4S3S2S1S3S2S1$14.3$12.5$10.7$8.9$7.1$$12$12Jul 23Apr 24Jan 25Oct 25Aug 26
S4S3S2S1S3S2S1$14.3$12.5$10.7$8.9$7.1$$12$12Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2021 Each cell is one week from 2021 to now (271 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jun 21Aug 26

Against the market, two honest reads. Cumulative: over the last 5.2 years the stock moved +20% while the S&P 500 moved +83% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

Hagerty, Inc. trades at 5.4× P/BV, near the bottom of its own range — cheaper only 15% of the time. Its long-run median P/BV is 10.4×, measured across 5.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 5.4× is near the bottom of its own range — cheaper only 15% of the time, against a long-run median of 10.4× measured over 5.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: the net margin is the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

P/BV 5.4× vs a 10.4× long-run median P/BV, weekly (left axis); book value per share, quarterly steps drawn weekly (right axis). 5.1-year window; brief peaks above 31× shown pinned at the top. The book value / share bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 15% of the time
P/BVMedianBook value / share (quarterly)
33.6×$9.325.2×$7.016.8×$4.78.4×$2.30.0×$0.0×$5.41×$2Jul 21Oct 22Jan 24Apr 25Aug 26
33.6×$9.325.2×$7.016.8×$4.78.4×$2.30.0×$0.0×$5.41×$2Jul 21Jan 24Aug 26
PEG 0.14 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Computed here as quarter-end P/E ÷ trailing-twelve-month EPS growth (only quarters with positive growth), because a reported quarterly PEG is not held for this stock. Last 6 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
3.6×2.7×1.8×0.9×0.0××0.14×Jun 24Dec 24Mar 25Jun 25Dec 25
3.6×2.7×1.8×0.9×0.0××0.14×Jun 24Mar 25Dec 25
P/BV
5.4×
15th percentile of 5y
PEG
1.57
as reported

Why the multiple sits where it does: over the past year book value grew while the price moved +17.0% — price and book moved together, holding the multiple in its range.

The price move, decomposed: over 5y, of the +3.6%/yr price move, ~+12.9%/yr came from book-value growth and ~−9.3 pp from the multiple (compressing). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the book-value line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Hagerty, Inc. reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROE holding at 18.5% — the per-curve reads carry the story. The read is built from 12 quarters across 3 curves, on partial evidence.

Growth, year by year: revenue +17.7% in FY25, profit +87.5% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
31%291%28%216%24%141%20%65%17%−9.6%%%17.7%87.5%FY21FY23FY25
31%291%28%216%24%141%20%65%17%−9.6%%%17.7%87.5%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit rolling over
RevenueProfitEPS
30%335%26%209%22%83%18%−42%14%−168%%%16%−133.3%0%Jun 23Sep 24Mar 26
30%335%26%209%22%83%18%−42%14%−168%%%16%−133.3%0%Jun 23Sep 24Mar 26
ROE Trailing-twelve-month net profit as a share of quarter-end equity, %.
the return curve, computed quarterly
ROE
24%17%9.8%2.6%−4.6%%18.5%Jun 23Dec 23Sep 24Jun 25Mar 26
24%17%9.8%2.6%−4.6%%18.5%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +16.0% · span +15.5% to +28.7%
Profit growth
Falling
latest −133.3% · span −100.0% to +100.0%
ROE
Steady high
latest 18.5% · span −2.6%–22.2%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+17.7%+22.7%
Profit+87.5%
EPS+270.0%
Stock price+17.0%+11.6%+3.6%
Revenue YoY (Mar 26)
−6.1%
latest quarter vs a year ago
Profit YoY (Mar 26)
−133.3%
latest quarter vs a year ago
Revenue 10y
23.9%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

32.2/100 — rank 26 of 30 in Insurance - Property & Casualty · 64% evidence confidence

Hagerty, Inc. scores 32.2 out of 100 against the 30 companies it is compared with in Insurance - Property & Casualty, ranking 26. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 13.1 + 4.9 + 9.1 + 5.1 = 32.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.

Hagerty, Inc. reported $0.3 B of income in the Mar 26 quarter, −6.1% year on year. Over 4 years it has compounded at 23.9% a year. The last full year, FY25, came in at $1.5 B. The last four reported quarters add to $1.5 B.

FY25 revenue came in at $1.5 B (+17.7% on the year), capping 4 years at 23.9% compound. The latest quarter (Mar 26) printed $0.3 B, −6.1% year on year.

FY25 revenue $1.5 B (+17.7% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
23.9% a year over 4 years
RevenueYoY growth
1.631%1.228%0.824%0.420%0.017%$ B%$2B17.7%FY21FY23FY25
1.631%1.228%0.824%0.420%0.017%$ B%$2B17.7%FY21FY23FY25
Mar 26: $0.3 B (−6.1% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.438%0.326%0.214%0.12.5%0.0−9.4%$ B%$0B−6.1%Jun 23Sep 24Mar 26
0.438%0.326%0.214%0.12.5%0.0−9.4%$ B%$0B−6.1%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +16.7% growth against the decade's 23.9% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +16.0% over the last 4 quarters against +15.9%/yr over the last 8 — stabilising; TTM profit +20.0% vs +41.4%/yr — rolling over.

06 · Net margin

Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.

Hagerty, Inc.'s net margin is −3.2% in the Mar 26 quarter, −12.3 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the net margin has ranged −9.7% to 10.3%. The current quarter sits inside that band.

The latest quarter's net margin is −3.2%, −12.3 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged −9.7%–10.3%, and FY25's 10.3% is the top of that band — a record year.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 10.3% Net margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a −9.7–10.3% band over 5 years
net marginYoY change (pp)
12%10%6.1%8.3%0.3%6.3%−5.5%4.3%−11%2.4%%%10.3%3.8%FY21FY23FY25
12%10%6.1%8.3%0.3%6.3%−5.5%4.3%−11%2.4%%%10.3%3.8%FY21FY23FY25
Mar 26: −3.2% net margin (−12.3 pp YoY) Quarterly net margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Net profit as a share of total revenue, per quarter.
Net marginYoY change (pp)
15%21%10.0%12%5.2%3.2%0.3%−5.8%−4.5%−15%%%−3.2%−12.3%Jun 23Sep 24Mar 26
15%21%10.0%12%5.2%3.2%0.3%−5.8%−4.5%−15%%%−3.2%−12.3%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Hagerty, Inc. posted a net loss of $0.01 B in the Mar 26 quarter. Full-year FY25 profit was $0.1 B. That loss is 3.2% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 1 of the last 12 reported quarters were loss-making.

Mar 26 profit was $−0.0 B, −133.3% year on year. On the full year, FY25 printed $0.1 B (+87.5%).

FY25 profit $0.1 B (+87.5% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.17173%0.11150%0.05127%−0.02104%−0.0881%$ B%$0B87.5%FY21FY23FY25
0.17173%0.11150%0.05127%−0.02104%−0.0881%$ B%$0B87.5%FY21FY23FY25
Mar 26: $−0.0 B (−133.3% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.05227%0.04130%0.0233%0.00−63%−0.01−160%$ B%$0B−133.3%Jun 23Sep 24Mar 26
0.05227%0.04130%0.0233%0.00−63%−0.01−160%$ B%$0B−133.3%Jun 23Sep 24Mar 26

🚨 Why profit moved: revenue contributed −6.1% and the margin −12.3 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +60.4% vs revenue +16.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Asset quality — the ladder

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for Hagerty, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

09 · The loan book

The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

Hagerty, Inc.'s revenue grew +17.7% in FY25 to $1.5 B, so the book is growing. The latest quarter ran −6.1% year on year. The net margin on that income is −3.2%, −12.3 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.

FY25 revenue was $1.5 B, +17.7% on the year, and the latest quarter ran −6.1% year on year. The net margin on that revenue is −3.2% this quarter (−12.3 pp YoY) — growth with a narrowing margin on it.

FY25: revenue $1.5 B (+17.7% YoY) with the net margin at 10.3% Revenue by fiscal year, $ B (bars, left); net margin, % (line, right). 5-year window. A bar is red when it is lower than the year before.
RevenueNet margin
1.612%1.26.1%0.80.3%0.4−5.5%0.0−11%$ B%$2B10.3%FY21FY22FY23FY24FY25
1.612%1.26.1%0.80.3%0.4−5.5%0.0−11%$ B%$2B10.3%FY21FY23FY25

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.

10 · Returns on equity and assets

Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.

Hagerty, Inc. earns a return on equity of 11% in FY25. Its trough over the ladder below was −22% in FY21. On the asset side every $100 of the balance sheet earned about $5.98, which is the return before leverage is applied.

FY25 ROE came in at 11%, recovered from a FY21 trough of −22%. On assets, the latest reading is about 5.98% — every $100 the bank deploys earns roughly $5.98 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.

FY25: ROE 11%, ROA 8.80% Return on equity by fiscal year, % (line, left); return on assets, % (line, right). 5-year window. A lender is judged on ROE and ROA — return on invested capital does not apply to a bank.
up from a FY21 trough of −22%
ROEROA
14%9.7%4.3%6.5%−5.4%3.4%−15%0.2%−25%−3.0%%%11.4%8.8%FY21FY23FY25
14%9.7%4.3%6.5%−5.4%3.4%−15%0.2%−25%−3.0%%%11.4%8.8%FY21FY23FY25
Mar 26: ROE 17.3% (TTM), ROA 11.40% Trailing-twelve-month return on equity (left) and on assets (right), per quarter, %. Last 12 quarters, anchored to the annual figure.
ROE (TTM)ROA (TTM)
28%15%19%9.3%9.9%3.3%1.1%−2.7%−7.7%−8.8%%%17.3%11.4%Jun 23Sep 24Mar 26
28%15%19%9.3%9.9%3.3%1.1%−2.7%−7.7%−8.8%%%17.3%11.4%Jun 23Sep 24Mar 26

Why: the ROE ladder shows the move; the deposit-cost and provisioning drivers behind it sit below what we hold.

11 · Dividend

Dividend

Hagerty, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Hagerty, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

2.5% of Hagerty, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 7.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 2.5% of the float is sold short, and at typical trading volumes it would take about 7.3 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
2.5%
of the tradable float
Days to cover
7.3
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Hagerty, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

15 · Related companies · Insurance - Property & Casualty
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1The Allstate CorporationALL 69.3/100Favorable setup76% evidence BREAKING OUT 24.5/35 Income 4.4% · PAT 100% 71% evidence 15.6/25 ROA 2.1% · ROE 9.2% · GNPA — 68% evidence 12.2/20 P/BV 1.69× · P/BV÷ROE 0.18 70% evidence 17.0/20 RS sector 8.8% · RS bench 10.4% · 1Y 27%6 of 12 weeks ahead 100% evidence
Exact sum: 24.5 + 15.6 + 12.2 + 17 = 69.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Slide Insurance Holdings, Inc.SLDE 68.5/100Thin evidence · provisional54% evidence TURNING 20.5/35 Income — · PAT — 26% evidence 20.0/25 ROA 4.2% · ROE 13.1% · GNPA — 68% evidence 13.5/20 P/BV 1.87× · P/BV÷ROE 0.14 70% evidence 14.5/20 RS sector 5.5% · RS bench 7.2% · 1Y 20.5%3 of 12 weeks ahead 70% evidence
Exact sum: 20.5 + 20 + 13.5 + 14.5 = 68.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3The Travelers Companies, Inc.TRV 60.2/100Mixed-positive evidence60% evidence BREAKING OUT 20.1/35 Income — · PAT — 26% evidence 14.5/25 ROA 1.6% · ROE 7% · GNPA — 68% evidence 7.5/20 P/BV 2.08× · P/BV÷ROE 0.3 70% evidence 18.1/20 RS sector 12.1% · RS bench 13.8% · 1Y 42.4%4 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 14.5 + 7.5 + 18.1 = 60.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Mercury General CorporationMCY 57.8/100Mixed-positive evidence67% evidence FADING 22.2/35 Income 9.7% · PAT 100% 45% evidence 15.1/25 ROA 2.1% · ROE 8.6% · GNPA — 68% evidence 9.8/20 P/BV 1.89× · P/BV÷ROE 0.22 70% evidence 10.7/20 RS sector 3% · RS bench 4.7% · 1Y 50.5%7 of 12 weeks ahead 100% evidence
Exact sum: 22.2 + 15.1 + 9.8 + 10.7 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Skyward Specialty Insurance Group, Inc.SKWD 57.0/100Mixed-positive evidence76% evidence BREAKING OUT 19.9/35 Income 28.9% · PAT 43.5% 71% evidence 11.7/25 ROA 1.1% · ROE 4.8% · GNPA — 68% evidence 6.6/20 P/BV 1.59× · P/BV÷ROE 0.33 70% evidence 18.8/20 RS sector 12.2% · RS bench 13.7% · 1Y 26.4%8 of 12 weeks ahead 100% evidence
Exact sum: 19.9 + 11.7 + 6.6 + 18.8 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6United Fire Group, Inc.UFCS 56.8/100Mixed-positive evidence70% evidence LEADER 22.9/35 Income 10.6% · PAT 97% 71% evidence 9.3/25 ROA 0.9% · ROE 3.4% · GNPA — 68% evidence 7.9/20 P/BV 1× · P/BV÷ROE 0.29 70% evidence 16.7/20 RS sector 21.9% · RS bench 24.1% · 1Y 84.7%11 of 12 weeks ahead 70% evidence
Exact sum: 22.9 + 9.3 + 7.9 + 16.7 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7HCI Group, Inc.HCI 55.2/100Mixed-positive evidence62% evidence BREAKING OUT 22.5/35 Income 22.1% · PAT 100% 55% evidence 13.9/25 ROA — · ROE 9.9% · GNPA — 34% evidence 11.7/20 P/BV 1.83× · P/BV÷ROE 0.18 70% evidence 7.1/20 RS sector -7.7% · RS bench -6.5% · 1Y 27.4%6 of 12 weeks ahead 100% evidence
Exact sum: 22.5 + 13.9 + 11.7 + 7.1 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Cincinnati Financial CorporationCINF 54.8/100Mixed-positive evidence60% evidence BREAKING OUT 21.3/35 Income — · PAT — 26% evidence 16.4/25 ROA 3.1% · ROE 8.1% · GNPA — 68% evidence 10.7/20 P/BV 1.7× · P/BV÷ROE 0.21 70% evidence 6.4/20 RS sector -3.4% · RS bench -1.9% · 1Y 19.5%4 of 12 weeks ahead 100% evidence
Exact sum: 21.3 + 16.4 + 10.7 + 6.4 = 54.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9The Hanover Insurance Group, Inc.THG 53.7/100Mixed-positive evidence60% evidence BREAKING OUT 18.0/35 Income — · PAT — 26% evidence 13.5/25 ROA 1.6% · ROE 5.6% · GNPA — 68% evidence 5.9/20 P/BV 2.03× · P/BV÷ROE 0.36 70% evidence 16.3/20 RS sector 9.2% · RS bench 10.9% · 1Y 35%7 of 12 weeks ahead 100% evidence
Exact sum: 18 + 13.5 + 5.9 + 16.3 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10RLI Corp.RLI 52.9/100Mixed-positive evidence60% evidence TURNING 20.7/35 Income — · PAT — 26% evidence 17.5/25 ROA 2.7% · ROE 9.6% · GNPA — 68% evidence 6.5/20 P/BV 3.09× · P/BV÷ROE 0.32 70% evidence 8.2/20 RS sector -9.3% · RS bench -8.2% · 1Y -7.1%3 of 12 weeks ahead 100% evidence
Exact sum: 20.7 + 17.5 + 6.5 + 8.2 = 52.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
11W. R. Berkley CorporationWRB 52.3/100Mixed-positive evidence60% evidence TURNING 21.6/35 Income — · PAT — 26% evidence 17.9/25 ROA 2.2% · ROE 9.7% · GNPA — 68% evidence 8.3/20 P/BV 2.54× · P/BV÷ROE 0.26 70% evidence 4.5/20 RS sector -9.6% · RS bench -8.4% · 1Y 2.1%3 of 12 weeks ahead 100% evidence
Exact sum: 21.6 + 17.9 + 8.3 + 4.5 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Assurant, Inc.AIZ 52.0/100Mixed-positive evidence76% evidence BREAKING OUT 22.1/35 Income 9% · PAT 49% 71% evidence 10.8/25 ROA 0.8% · ROE 4.9% · GNPA — 68% evidence 5.7/20 P/BV 1.84× · P/BV÷ROE 0.38 70% evidence 13.4/20 RS sector 6.2% · RS bench 7.9% · 1Y 38.4%11 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 10.8 + 5.7 + 13.4 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Palomar Holdings, Inc.PLMR 48.7/100Mixed-negative evidence62% evidence TURNING 21.8/35 Income 60.4% · PAT 47% 55% evidence 11.9/25 ROA — · ROE 4.9% · GNPA — 34% evidence 3.3/20 P/BV 3.3× · P/BV÷ROE 0.67 70% evidence 11.7/20 RS sector -2.2% · RS bench -0.9% · 1Y 13.1%3 of 12 weeks ahead 100% evidence
Exact sum: 21.8 + 11.9 + 3.3 + 11.7 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Kinsale Capital Group, Inc.KNSL 48.1/100Mixed-negative evidence60% evidence TURNING 18.8/35 Income — · PAT — 26% evidence 18.1/25 ROA 3% · ROE 9.4% · GNPA — 68% evidence 4.8/20 P/BV 3.69× · P/BV÷ROE 0.39 70% evidence 6.4/20 RS sector -15.2% · RS bench -14.2% · 1Y -17.3%2 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 18.1 + 4.8 + 6.4 = 48.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
15Selective Insurance Group, Inc.SIGI 46.0/100Mixed-negative evidence60% evidence BREAKING OUT 18.3/35 Income — · PAT — 26% evidence 10.3/25 ROA 0.9% · ROE 3.7% · GNPA — 68% evidence 5.1/20 P/BV 1.58× · P/BV÷ROE 0.43 70% evidence 12.3/20 RS sector 2.1% · RS bench 3.7% · 1Y 23.6%9 of 12 weeks ahead 100% evidence
Exact sum: 18.3 + 10.3 + 5.1 + 12.3 = 46 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Markel Group Inc.MKL 45.5/100Mixed-negative evidence60% evidence BASING 20.5/35 Income — · PAT — 26% evidence 14.6/25 ROA 1.8% · ROE 6.3% · GNPA — 68% evidence 8.6/20 P/BV 1.28× · P/BV÷ROE 0.2 70% evidence 1.8/20 RS sector -15.2% · RS bench -14% · 1Y -1.2%0 of 12 weeks ahead 100% evidence
Exact sum: 20.5 + 14.6 + 8.6 + 1.8 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Old Republic International CorporationORI 44.8/100Mixed-negative evidence60% evidence TURNING 20.2/35 Income — · PAT — 26% evidence 11.8/25 ROA 1.1% · ROE 5.3% · GNPA — 68% evidence 7.3/20 P/BV 1.64× · P/BV÷ROE 0.31 70% evidence 5.5/20 RS sector -7.1% · RS bench -5.9% · 1Y 16.2%2 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 11.8 + 7.3 + 5.5 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18The Progressive CorporationPGR 43.6/100Mixed-negative evidence60% evidence FADING 14.9/35 Income — · PAT — 26% evidence 18.1/25 ROA 2.8% · ROE 9.9% · GNPA — 68% evidence 5.3/20 P/BV 3.61× · P/BV÷ROE 0.36 70% evidence 5.3/20 RS sector -14.1% · RS bench -13% · 1Y -14.5%2 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 18.1 + 5.3 + 5.3 = 43.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
19Safety Insurance Group, Inc.SAFT 42.0/100Thin evidence · provisional58% evidence TURNING 10.0/35 Income 10.8% · PAT -13.7% 71% evidence 5.8/25 ROA -0.6% · ROE -1.7% · GNPA — 68% evidence 9.8/20 P/BV 1.25× · P/BV÷ROE — 10% evidence 16.4/20 RS sector 20.4% · RS bench 22.1% · 1Y 45.5%3 of 12 weeks ahead 70% evidence
Exact sum: 10 + 5.8 + 9.8 + 16.4 = 42 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Horace Mann Educators CorporationHMN 41.6/100Mixed-negative evidence76% evidence BREAKING OUT 17.4/35 Income 5.5% · PAT 43.9% 71% evidence 7.5/25 ROA 0.3% · ROE 2.9% · GNPA — 68% evidence 5.3/20 P/BV 1.17× · P/BV÷ROE 0.4 70% evidence 11.4/20 RS sector 0.1% · RS bench 1.6% · 1Y 17.8%7 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 7.5 + 5.3 + 11.4 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21White Mountains Insurance Group, Ltd.WTM 40.1/100Mixed-negative evidence64% evidence ASLEEP 21.4/35 Income 69.3% · PAT 100% 71% evidence 5.8/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence 3.1/20 RS sector -8.7% · RS bench -7.2% · 1Y 20.9%0 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 5.8 + 9.8 + 3.1 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Chubb LimitedCB 38.8/100Mixed-negative evidence60% evidence TURNING 14.8/35 Income — · PAT — 26% evidence 11.7/25 ROA 1.1% · ROE 3.7% · GNPA — 68% evidence 4.6/20 P/BV 1.75× · P/BV÷ROE 0.47 70% evidence 7.7/20 RS sector -1.4% · RS bench 0.2% · 1Y 28.4%1 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 11.7 + 4.6 + 7.7 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23CNA Financial CorporationCNA 38.6/100Mixed-negative evidence76% evidence TURNING 14.0/35 Income 4% · PAT 35.8% 71% evidence 7.7/25 ROA 0.3% · ROE 2% · GNPA — 68% evidence 4.2/20 P/BV 1.14× · P/BV÷ROE 0.57 70% evidence 12.7/20 RS sector -0.8% · RS bench 0.6% · 1Y 12.7%3 of 12 weeks ahead 100% evidence
Exact sum: 14 + 7.7 + 4.2 + 12.7 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Stewart Information Services CorporationSTC 36.7/100Mixed-negative evidence60% evidence ASLEEP 17.3/35 Income — · PAT — 26% evidence 12.6/25 ROA 1.6% · ROE 2.7% · GNPA — 68% evidence 4.8/20 P/BV 1.21× · P/BV÷ROE 0.45 70% evidence 2.0/20 RS sector -12.4% · RS bench -11.2% · 1Y 1.8%0 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 12.6 + 4.8 + 2 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Loews CorporationL 32.9/100Adverse evidence76% evidence TURNING 14.5/35 Income 4.2% · PAT 23.8% 71% evidence 7.9/25 ROA 0.5% · ROE 1.9% · GNPA — 68% evidence 4.0/20 P/BV 1.17× · P/BV÷ROE 0.62 70% evidence 6.5/20 RS sector -3.2% · RS bench -1.7% · 1Y 23.7%1 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 7.9 + 4 + 6.5 = 32.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Hagerty, Inc.this pageHGTY 32.2/100Adverse evidence64% evidence TURNING 13.1/35 Income 15.4% · PAT 12.4% 71% evidence 4.9/25 ROA -0.6% · ROE -2.2% · GNPA — 68% evidence 9.1/20 P/BV 4.87× · P/BV÷ROE — 10% evidence 5.1/20 RS sector -11.6% · RS bench -10.4% · 1Y 10%4 of 12 weeks ahead 100% evidence
Exact sum: 13.1 + 4.9 + 9.1 + 5.1 = 32.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27American Financial Group, Inc.AFG 29.7/100Adverse evidence76% evidence TURNING 11.9/35 Income -1.2% · PAT 10% 71% evidence 9.8/25 ROA 0.6% · ROE 4.2% · GNPA — 68% evidence 4.1/20 P/BV 2.27× · P/BV÷ROE 0.54 70% evidence 3.9/20 RS sector -7.9% · RS bench -6.6% · 1Y 8.7%1 of 12 weeks ahead 100% evidence
Exact sum: 11.9 + 9.8 + 4.1 + 3.9 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Kemper CorporationKMPR 24.7/100Thin evidence · provisional58% evidence BASING 6.2/35 Income 0.3% · PAT -90.6% 71% evidence 5.7/25 ROA 0% · ROE -0.2% · GNPA — 68% evidence 9.8/20 P/BV 0.68× · P/BV÷ROE — 10% evidence 3.0/20 RS sector -30.2% · RS bench -29.5% · 1Y -41.5%0 of 12 weeks ahead 70% evidence
Exact sum: 6.2 + 5.7 + 9.8 + 3 = 24.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Porch Group, Inc.PRCH 47.6/100Thin evidence · provisional48% evidence BREAKING OUT 13.2/35 Income — · PAT — 26% evidence 4.6/25 ROA -0.5% · ROE -164.7% · GNPA — 68% evidence 9.8/20 P/BV -143.74× · P/BV÷ROE — 10% evidence 20.0/20 RS sector 28.2% · RS bench 29.5% · 1Y 16.3%12 of 12 weeks ahead 100% evidence
Exact sum: 13.2 + 4.6 + 9.8 + 20 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Lemonade, Inc.LMND 30.7/100Thin evidence · provisional48% evidence ASLEEP 17.3/35 Income — · PAT — 26% evidence 4.1/25 ROA -2.2% · ROE -8.5% · GNPA — 68% evidence 9.0/20 P/BV 10× · P/BV÷ROE — 10% evidence 0.3/20 RS sector -24% · RS bench -23% · 1Y 10.5%1 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 4.1 + 9 + 0.3 = 30.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Hagerty, Inc.'s stock price today?

Hagerty, Inc. trades at $11.7, +17.0% over the past year. The company is valued at $4.0 B. The stock sits at 44% of its 52-week range of $10–$14, +0.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 1 weeks in. — as of 5 August 2026.

What were Hagerty, Inc.'s latest quarterly results?

Hagerty, Inc. reported total income of $0.3 B and a net loss of $0.0 B for the Mar 26 quarter. Income fell 6.1% and profit fell 133.3% year on year. Earnings per share were $−0.06. The net margin was −3.2%, 12.3 pp lower than a year earlier. — as of 5 August 2026.

What is Hagerty, Inc.'s revenue?

Hagerty, Inc. reported revenue of $0.3 B in the Mar 26 quarter, −6.1% year on year. For the full FY25 fiscal year, revenue was $1.5 B (+17.7%). Over the last 4 years revenue compounded at 23.9% a year. — as of 5 August 2026.

What is Hagerty, Inc.'s profit?

Hagerty, Inc. earned $−0.0 B of net profit in the Mar 26 quarter, −133.3% year on year. Full-year FY25 profit was $0.1 B. The net margin ran −3.2% in the latest quarter. — as of 5 August 2026.

What is Hagerty, Inc.'s market cap?

Hagerty, Inc.'s market capitalisation is $4.0 B at a stock price of $11.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Hagerty, Inc.'s P/BV ratio?

Hagerty, Inc. trades at a P/BV of 5.4×, at the 15th percentile of its own 5-year range, against a long-run median of 10.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Hagerty, Inc. pay a dividend?

No — Hagerty, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

Is Hagerty, Inc. overvalued?

On its own history, Hagerty, Inc. looks cheap against its own history: its P/BV of 5.4× has been cheaper only 15% of the time in 5 years (long-run median 10.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: the net margin is the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.

Is Hagerty, Inc. growing?

Not right now — Hagerty, Inc.'s latest numbers are shrinking: latest-quarter revenue −6.1% year on year, profit −133.3%, and the the net margin −12.3 pp at −3.2%. The earnings engine currently reads: deteriorating — as of 5 August 2026.

How is Hagerty, Inc. performing?

Hagerty, Inc. is in a confirmed uptrend, 1 weeks in. Its latest quarter's income fell 6.1% and profit fell 133.3% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Hagerty, Inc. in?

Mixed — no clean majority across the growth curves, ROE holding at 18.5% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +16.0% latest, profit growth −133.3% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Hagerty, Inc. in an uptrend?

Yes — the price is in a confirmed uptrend (week 1 of stage 2), trading +0.7% versus its 200-day average and at 44% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Hagerty, Inc. beating the market?

On recent form, yes — Hagerty, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.2 years the stock moved +20% against the S&P 500's +83% — behind the index over the full window. — as of 5 August 2026.

Will Hagerty, Inc.'s stock price go up?

This page publishes no price forecast for Hagerty, Inc. What it measures instead: the stock price is $11.7, the price is in a confirmed uptrend 1 weeks in. Its P/BV of 5.4× sits at the 15th percentile of its own 5-year range. — as of 5 August 2026.

Is the market betting against Hagerty, Inc.?

Somewhat — short interest is 2.5% of Hagerty, Inc.'s tradable float, about 7.3 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Is Hagerty, Inc.'s loan book healthy?

We do not hold quarterly loan-book quality numbers for Hagerty, Inc., so this page says that plainly. The cleanest available reads are revenue growth (+17.7% in FY25) and the net margin on it (−3.2%) — as of 5 August 2026.

Where is Hagerty, Inc. in its business cycle?

Hagerty, Inc.'s FY25 net margin was 10.3%, against a 5-year band of −9.7%–10.3%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran −3.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Hagerty, Inc. story?

The sharpest disagreement: annual EPS moved +270.0% against a +17.0% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Hagerty, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Hagerty, Inc. is cheap for a reason. The P/BV sits at the 15th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI